Sickle Cell Disease
Overview
Sickle cell disease is a devastating and debilitating genetic condition that affects up to 10 million people worldwide. The disease continues to severely impact quality of life and longevity. Highly efficacious oral drug therapies are urgently needed to manage this condition on a global scale.
Learn MoreOur Science
Pipeline
We are focused on advancing next generation oral therapies for the treatment of sickle cell disease. Our goal is to develop best-in-class oral Hemoglobin S polymerization inhibitors that can provide profound disease-modifying clinical benefits. Our lead drug ILX002 is the first of its kind that binds to Hemoglobin S and directly blocks polymerization and sickling.
Learn More